Q-omics provides the consensus-scored PRR35 profile across patient tissues and cancer cell-line models. PRR35 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRR35 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, PRR35 RNA expression shows 8,134 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where PRR35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR35 survival associations across molecular data types. PRR35 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR35 RNA expression–survival associations across cancer types. High PRR35 expression shows unfavorable associations in ACC, DLBC, SCLC, KIRC and LIHC, but favorable associations in KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRR35 RNA expression.
This table summarizes PRR35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRR35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR35 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in BRCA, LIHC and LUSC. The KIRC box plot shows higher PRR35 RNA expression in normal versus tumor tissue (log2 FC = −3.792, t-test p < 0.001).
This table shows molecular features associated with PRR35 in patient tissues and cancer cell lines. In patient samples, PRR35 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
